ストックスクリーナーアプリを入手
10.39
0.57%
-0.06
前日終値:
$10.45
開ける：
$10.46
24時間の取引高:
368.58K
Relative Volume:
0.53
時価総額：
$851.01M
収益：
-
当期純損益:
$-209.96M
株価収益率:
-3.288
EPS:
-3.16
ネットキャッシュフロー:
$-176.27M
1週間 パフォーマンス:
-3.97%
1か月 パフォーマンス:
-17.77%
6か月 パフォーマンス:
-6.90%
1年 パフォーマンス:
+27.17%
1日の値動き範囲:
$10.12
$10.61
1週間の範囲:
$10.12
$11.23
52週間の値動き範囲:
$4.92
$17.00
Replimune Group Inc Stock (REPL) Company Profile
REPL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
10.39 | 851.01M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2023-04-17 | 再開されました | Piper Sandler | Overweight |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2020-11-17 | 開始されました | BTIG Research | Buy |
| 2020-11-02 | 開始されました | Jefferies | Buy |
| 2020-10-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2019-09-04 | 開始されました | ROTH Capital | Buy |
| 2019-07-23 | 開始されました | Chardan Capital Markets | Buy |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-25 | 開始されました | Wedbush | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 開始されました | JP Morgan | Overweight |
| 2018-08-14 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Replimune Group Inc (REPL) 最新ニュース
Charles Schwab Investment Management Inc. Has $6.16 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Victory Capital Management Inc. Purchases Shares of 44,880 Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Bank of New York Mellon Corp Increases Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Holdings Cut by AlphaQuest LLC - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.43 Average Price Target from Analysts - Defense World
Arizona State Retirement System Invests $156,000 in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Financial Metrics Check: Replimune Group Inc (REPL)’s Ratios for Trailing Twelve Months - The Dwinnex
Replimune Group Appoints New Director, Grants Stock Options By Investing.com - Investing.com Australia
Replimune Group Appoints New Director, Grants Stock Options - Investing.com
Replimune Group Appoints Michael Goller To Board, Increases Board Size To Ten -March 07, 2025 at 05:04 pm EST - Marketscreener.com
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -March 07, 2025 at 04:11 pm EST - Marketscreener.com
Rhumbline Advisers Grows Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs - Bain Capital
New York State Common Retirement Fund Purchases 31,231 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
JPMorgan Chase & Co. Increases Replimune Group (NASDAQ:REPL) Price Target to $18.00 - MarketBeat
Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 - Defense World
Replimune Group (NASDAQ:REPL) Stock Price Up 6.1%What's Next? - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.29 Average Price Target from Brokerages - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Short Interest Update - MarketBeat
Replimune's SWOT analysis: oncolytic immunotherapy stock poised for FDA approval - Investing.com
Possible Bearish Signals With Replimune Group Insiders Disposing Stock - Simply Wall St
Leerink Partnrs Predicts Weaker Earnings for Replimune Group - Defense World
FY2025 EPS Estimates for Replimune Group Lowered by Wedbush - MarketBeat
Replimune Group (NASDAQ:REPL) Announces Quarterly Earnings Results - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock - MarketBeat
Replimune stock target raised to $22 at H.C. Wainwright - MSN
Navigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global Risks - MSN
Replimune stock target raised to $22 at H.C. Wainwright By Investing.com - Investing.com Australia
Replimune: A Misunderstood Contender In Oncolytics (NASDAQ:REPL) - Seeking Alpha
Wedbush Raises Replimune Group's Price Target to $19 From $16, Keeps Outperform Rating - Marketscreener.com
Replimune Group Inc. (REPL) reports earnings - Quartz
Replimune Group, Inc. SEC 10-Q Report - TradingView
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
FDA Fast-Tracks Replimune's Melanoma Treatment as Cash Reserves Hit $536M in Q3 Report - StockTitan
Top Wealth Group Holding Ltd (TWG)’s financial ratios: A comprehensive overview - The Dwinnex
Metric Analysis: Nvni Group Ltd (NVNI)’s Key Ratios in the Limelight - The Dwinnex
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
How to Take Advantage of moves in (REPL) - Stock Traders Daily
Replimune's Strategic Move: $14.25 Stock Options Package Secures Top Talent - StockTitan
Replimune Group (REPL) Expected to Announce Earnings on Thursday - Defense World
Replimune Group Inc (REPL) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):